Logo ADMA Biologics, Inc. - ADMA 19.69 USD

P/E
143.07
EPS
0.14
P/B
24.79
ROE
20.77
Beta
0.62
Target Price
19.00 USD

19.690 USD

19.690 USD

Daily: +2.55%
Key Metrics

P/E: 143.07

EPS: 0.14

Book Value: 0.81

Price to Book: 24.79

Debt/Equity: 75.10

% Insiders: 2.583%

Growth

Revenue Growth: 0.78%

Estimates

Forward P/E: 29.90

Forward EPS: 0.67

Target Mean Price: 19.00

 Logo About ADMA Biologics, Inc. - (ADMA)

Country: United States

Sector: Health Care

Website: http://www.admabiologics.com

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Exchange Ticker
NGM (Sweden) ADMA

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion